Ryan Werntz, MD, urologist, Oregon Health and Science University, discusses a study which examined trends in prostate-specific antigen (PSA) utilization in primary care physicians.
Ryan Werntz, MD, urologist, Oregon Health and Science University, discusses a study which examined trends in prostate-specific antigen (PSA) utilization in primary care physicians.
<<<
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More